Minerva Neurosciences (NASDAQ:NERV) Price Target Lowered to $7.00 at HC Wainwright

Minerva Neurosciences (NASDAQ:NERV) had its target price reduced by research analysts at HC Wainwright from $11.00 to $7.00 in a research report issued to clients and investors on Thursday, Benzinga reports. The brokerage currently has a “neutral” rating on the biopharmaceutical company’s stock. HC Wainwright’s price target suggests a potential upside of 186.89% from the stock’s current price.

Separately, StockNews.com lowered shares of Minerva Neurosciences from a “hold” rating to a “sell” rating in a report on Friday, February 23rd.

Minerva Neurosciences Price Performance

NASDAQ NERV traded up $0.04 during trading hours on Thursday, hitting $2.44. 5,782 shares of the company’s stock traded hands, compared to its average volume of 95,832. Minerva Neurosciences has a 52-week low of $2.29 and a 52-week high of $13.49. The company has a market capitalization of $17.06 million, a PE ratio of -0.51 and a beta of 0.27. The firm’s 50-day moving average is $2.85 and its 200-day moving average is $5.35.

Minerva Neurosciences (NASDAQ:NERV) last posted its quarterly earnings results on Thursday, February 22nd. The biopharmaceutical company reported ($1.19) earnings per share for the quarter, missing the consensus estimate of ($0.88) by ($0.31). Equities research analysts predict that Minerva Neurosciences will post -3.57 earnings per share for the current fiscal year.

About Minerva Neurosciences

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.